| 证券代码 | LACQU.O |
| 证券名称 | Leisure Acquisition Corp Unit Cons of 1 Sh + 0.5 Wts |
| 证券类型 | 美国普通单位 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2017-12-01 |
| 首发价格(元) | 10 USD |
| 首发数量(股) | 20000000 |
| 首发募资额(元) | 200,000,000.00 USD |
| 首发主承销商 | Morgan Stanley & Co. LLC |
| 货币单位 | USD |
| 公司名称 | Ensysce Biosciences, Inc. |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 7946 Ivanhoe Avenue, Suite 201, La Jolla, California, USA |
| 成立日期 | 2017-09-11 |
| 董事会主席 | Bob Gower |
| 公司属地 | United States 美国 |
| 公司网址 | www.ensysce.com |
| 电话 | +1 (858) 263-4196 |
| 传真 | - |
| 公司简介 | Ensysce Biosciences, Inc. is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. Leveraging its Trypsin Activated Abuse Protectionand Multi-Pill Abuse Resistance platforms, the Company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Ensysce’s products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing the human and economic cost. The platforms are covered by an extensive worldwide intellectual property portfolio for a wide array of prescription drug compositions. |